These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 38665034)

  • 1. Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication.
    Huang CF; Awad MH; Gal-Tanamy M; Yu ML
    Clin Mol Hepatol; 2024 Jul; 30(3):326-344. PubMed ID: 38665034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication.
    Lu MY; Yeh ML; Huang CI; Wang SC; Tsai YS; Tsai PC; Ko YM; Lin CC; Chen KY; Wei YJ; Hsu PY; Hsu CT; Jang TY; Liu TW; Liang PC; Hsieh MY; Lin ZY; Chen SC; Huang CF; Huang JF; Dai CY; Chuang WL; Yu ML
    World J Gastroenterol; 2022 Jan; 28(1):140-153. PubMed ID: 35125824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
    Tsai PC; Kuo HT; Hung CH; Tseng KC; Lai HC; Peng CY; Wang JH; Chen JJ; Lee PL; Chien RN; Yang CC; Lo GH; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Lin CY; Su WW; Chu CH; Chen CJ; Tung SY; Tai CM; Lin CW; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Yeh ML; Huang CF; Hsieh MH; Huang JF; Dai CY; Chung WL; Chen CY; Yu ML;
    J Hepatol; 2023 Feb; 78(2):281-292. PubMed ID: 36208843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV).
    Quaranta MG; Cavalletto L; Russo FP; Calvaruso V; Ferrigno L; Zanetto A; Mattioli B; D'Ambrosio R; Panetta V; Brancaccio G; Raimondo G; Brunetto MR; Zignego AL; Coppola C; Iannone A; Biliotti E; Rosselli Del Turco E; Massari M; Licata A; Barbaro F; Persico M; Morisco F; Pompili M; Cerini F; Puoti M; Santantonio T; Craxì A; Kondili LA; Chemello L; On Behalf Of Piter Collaborating Investigators
    Viruses; 2024 Apr; 16(5):. PubMed ID: 38793565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unmet Needs in the Post-Direct-Acting Antiviral Era: Hepatocarcinogenesis After Hepatitis C Virus Eradication.
    Przybyszewski EM; Chung RT
    J Infect Dis; 2023 Sep; 228(Suppl 3):S226-S231. PubMed ID: 37703341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular Carcinoma Incidences and Risk Factors in Hepatitis C Patients: Interferon versus Direct-Acting Agents.
    Kao YT; Liu YC; Cheng YT; Wen YW; Hsieh YC; Hsu CE; Su CW; Tai JC; Chen YC; Jeng WJ; Lin CY; Chien RN; Tai DI; Sheen IS
    Viruses; 2024 Sep; 16(9):. PubMed ID: 39339961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?
    Meringer H; Shibolet O; Deutsch L
    World J Gastroenterol; 2019 Aug; 25(29):3929-3940. PubMed ID: 31413528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular carcinoma and hepatitis C virus treatments: The bold and the beautiful.
    Abdelhamed W; El-Kassas M
    J Viral Hepat; 2023 Feb; 30(2):148-159. PubMed ID: 36461645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: Who to screen and for how long?
    Ahumada A; Rayón L; Usón C; Bañares R; Alonso Lopez S
    World J Gastroenterol; 2021 Oct; 27(40):6737-6749. PubMed ID: 34790004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the PNPLA3 genotype on the risk of hepatocellular carcinoma after hepatitis C virus eradication.
    Ohta A; Ogawa E; Murata M; Matsumoto Y; Yamasaki S; Ikezaki H; Furusyo N
    J Med Virol; 2022 Oct; 94(10):5007-5014. PubMed ID: 35652276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
    Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
    J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
    Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
    Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.
    Ji F; Yeo YH; Wei MT; Ogawa E; Enomoto M; Lee DH; Iio E; Lubel J; Wang W; Wei B; Ide T; Preda CM; Conti F; Minami T; Bielen R; Sezaki H; Barone M; Kolly P; Chu PS; Virlogeux V; Eurich D; Henry L; Bass MB; Kanai T; Dang S; Li Z; Dufour JF; Zoulim F; Andreone P; Cheung RC; Tanaka Y; Furusyo N; Toyoda H; Tamori A; Nguyen MH
    J Hepatol; 2019 Sep; 71(3):473-485. PubMed ID: 31096005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy.
    Huang CF; Yu ML
    Clin Mol Hepatol; 2020 Jul; 26(3):251-260. PubMed ID: 32188235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrahepatic immune changes after hepatitis c virus eradication by direct-acting antiviral therapy.
    Amaddeo G; Nguyen CT; Maillé P; Mulé S; Luciani A; Machou C; Rodrigues A; Regnault H; Mallat A; Laurent A; Lafdil F; Hézode C; Pawlotsky JM; Calderaro J
    Liver Int; 2020 Jan; 40(1):74-82. PubMed ID: 31444947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complex Association of Virus- and Host-Related Factors with Hepatocellular Carcinoma Rate following Hepatitis C Virus Clearance.
    Akuta N; Suzuki F; Sezaki H; Kobayashi M; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30381417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
    Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
    J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C.
    Ioannou GN; Green PK; Beste LA; Mun EJ; Kerr KF; Berry K
    J Hepatol; 2018 Nov; 69(5):1088-1098. PubMed ID: 30138686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of liver-stiffness measurement on hepatocellular carcinoma development in chronic hepatitis C patients treated with direct-acting antivirals: A systematic review and time-to-event meta-analysis.
    You MW; Kim KW; Shim JJ; Pyo J
    J Gastroenterol Hepatol; 2021 Mar; 36(3):601-608. PubMed ID: 32875681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.